Cogent Biosciences, Inc. Increase (Decrease) in Accounts Payable
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Accounts Payable of -$2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$6.26M, a 353.18% decline year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $4.24M, a 98.04% increase year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$6.53M.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$596.00K, a 109.79% decline year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$2.51M, a 284.76% decline from fiscal 2024.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.36M, a 71.78% decline from fiscal 2023.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2023 was $4.81M, a 104.03% increase from fiscal 2022.
- Cogent Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2022 was $2.36M, a 14.25% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.02M 10-Q · filed 2026-08-10 | -$8.54M derived: sum of 3 quarters · filed 2026-08-10 | -$9.14M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.24M 10-Q · filed 2026-05-05 | -$2.29M derived: sum of 2 quarters · filed 2026-05-05 | -$2.88M derived: sum of 3 quarters · filed 2026-05-05 | -$410.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$7.12M derived: sum of 2 quarters · filed 2026-02-17 | -$4.65M derived: sum of 3 quarters · filed 2026-08-10 | -$2.51M 10-K · filed 2026-02-17 |
| 2025-09-30 | -$596.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.88M derived: sum of 2 quarters · filed 2026-08-10 | $4.02M 10-Q · filed 2025-11-07 | $968.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.61M 10-Q · filed 2026-08-10 | $1.56M derived: sum of 3 quarters · filed 2026-08-10 | $7.65M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.14M 10-Q · filed 2026-05-05 | -$907.00K derived: sum of 2 quarters · filed 2026-05-05 | $5.18M derived: sum of 3 quarters · filed 2026-05-05 | -$1.41M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.04M derived: sum of 2 quarters · filed 2026-02-17 | -$3.55M derived: sum of 3 quarters · filed 2026-02-17 | $1.36M 10-K · filed 2026-02-17 |
| 2024-09-30 | $6.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$504.00K derived: sum of 2 quarters · filed 2025-11-07 | $4.41M 10-Q · filed 2025-11-07 | $5.19M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$6.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.68M 10-Q · filed 2025-08-05 | -$893.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.81M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $4.91M 10-Q · filed 2025-05-06 | $5.70M derived: sum of 2 quarters · filed 2026-02-17 | $8.40M derived: sum of 3 quarters · filed 2026-02-17 | $11.39M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.49M derived: sum of 2 quarters · filed 2026-02-17 | $6.48M derived: sum of 3 quarters · filed 2026-02-17 | $4.81M 10-K · filed 2026-02-17 |
| 2023-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.70M derived: sum of 2 quarters · filed 2024-11-12 | $4.03M 10-Q · filed 2024-11-12 | $5.78M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.32M 10-Q · filed 2024-08-06 | $3.07M derived: sum of 3 quarters · filed 2025-02-25 | $3.67M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$1.67M 10-Q · filed 2024-05-07 | $79.00K derived: sum of 2 quarters · filed 2025-02-25 | $680.00K derived: sum of 3 quarters · filed 2025-02-25 | $157.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.35M derived: sum of 2 quarters · filed 2025-02-25 | $1.83M derived: sum of 3 quarters · filed 2025-02-25 | $2.36M 10-K · filed 2025-02-25 |
| 2022-09-30 | $601.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $78.00K derived: sum of 2 quarters · filed 2023-11-07 | $610.00K 10-Q · filed 2023-11-07 | -$256.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.00K 10-Q · filed 2023-08-08 | -$857.00K derived: sum of 3 quarters · filed 2024-02-26 | $1.50M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $532.00K 10-Q · filed 2023-05-09 | -$334.00K derived: sum of 2 quarters · filed 2024-02-26 | $2.02M derived: sum of 3 quarters · filed 2024-02-26 | $3.70M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$866.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.49M derived: sum of 2 quarters · filed 2024-02-26 | $3.17M derived: sum of 3 quarters · filed 2024-02-26 | $2.75M 10-K · filed 2024-02-26 |
| 2021-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.03M derived: sum of 2 quarters · filed 2022-11-14 | $3.62M 10-Q · filed 2022-11-14 | $3.71M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.26M 10-Q · filed 2022-08-09 | $1.35M derived: sum of 3 quarters · filed 2022-08-09 | $1.36M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$417.00K 10-Q · filed 2022-05-10 | -$324.00K derived: sum of 2 quarters · filed 2022-05-10 | -$317.00K derived: sum of 3 quarters · filed 2022-05-10 | -$313.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $100.00K derived: sum of 2 quarters · filed 2022-03-15 | $104.00K derived: sum of 3 quarters · filed 2022-03-15 | -$2.45M 10-K · filed 2022-03-15 |
| 2020-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $11.00K derived: sum of 2 quarters · filed 2021-11-10 | -$2.54M 10-Q · filed 2021-11-10 | -$955.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$2.55M 10-Q · filed 2021-08-16 | -$962.00K derived: sum of 3 quarters · filed 2021-08-16 | -$1.03M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$2.56M 10-Q · filed 2021-05-12 | -$966.00K derived: sum of 2 quarters · filed 2021-05-12 | -$1.03M derived: sum of 3 quarters · filed 2021-05-12 | -$1.21M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.52M derived: sum of 2 quarters · filed 2021-03-16 | $1.35M derived: sum of 3 quarters · filed 2021-03-16 | $1.66M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$66.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$242.00K derived: sum of 2 quarters · filed 2020-11-09 | $75.00K 10-Q · filed 2020-11-09 | $791.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $141.00K 10-Q · filed 2020-08-11 | $857.00K derived: sum of 3 quarters · filed 2020-08-11 | $5.00K derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $317.00K 10-Q · filed 2020-05-11 | $1.03M derived: sum of 2 quarters · filed 2020-05-11 | $181.00K derived: sum of 3 quarters · filed 2020-05-11 | -$657.00K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $716.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$136.00K derived: sum of 2 quarters · filed 2020-03-26 | -$974.00K derived: sum of 3 quarters · filed 2020-03-26 | $367.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | -$852.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.69M derived: sum of 2 quarters · filed 2019-11-12 | -$349.00K 10-Q · filed 2019-11-12 | -$1.12M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$838.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $503.00K 10-Q · filed 2019-08-12 | -$271.00K derived: sum of 3 quarters · filed 2019-08-12 | $32.00K derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $1.34M 10-Q · filed 2019-05-13 | $567.00K derived: sum of 2 quarters · filed 2019-05-13 | $870.00K derived: sum of 3 quarters · filed 2019-05-13 | $1.37M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | -$774.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$471.00K derived: sum of 2 quarters · filed 2019-03-28 | $30.00K derived: sum of 3 quarters · filed 2019-03-28 | -$31.00K 10-K · filed 2019-03-28 |
| 2017-09-30 | $303.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $804.00K derived: sum of 2 quarters · filed 2018-11-13 | $743.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $440.00K 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | -$61.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |